HRT and Colorectal Cancer Risk: The Benefit Still Printed on the Label — and the 24-Year Data That Erased It

HRT and colorectal cancer risk is not the simple good-news story you've probably read. Randomized trials have not shown a clear overall increase. But the famous 44% reduction came from one oral trial arm in women with a uterus — and vanished after 24 years: 215 colorectal cancers with hormones versus 216 with placebo.

That's the answer. Here's the part almost nobody tells you: the reason the "benefit" disappeared may be the single most useful thing on this page, and it has nothing to do with whether you take hormones. It has to do with bleeding — and who gets believed when they report it.

We'll get there. First, the fast version.

Best for / not for you if

Best for	This page is not your next step if
You're weighing HRT and saw a claim that it protects your colon. Bowel cancer runs in your family. You've had colorectal cancer and want menopause treatment. You're on HRT and you're worried.	You have blood in or on your stool, black or tarry stool, a new bowel change that lasts more than a few days, unexplained weight loss, persistent abdominal pain, or unexplained anemia right now. Book an in-person evaluation. Continuous or heavy rectal bleeding, fainting or marked lightheadedness, or rectal bleeding with severe abdominal pain needs urgent or emergency care. [36]

The bottom line, at a glance

Question	Short answer
Does HRT cause colorectal cancer?	No clear overall increase has been shown in randomized trials.
Does HRT prevent colorectal cancer?	No. Don't start, continue, or choose a form of HRT for this reason.
What did the long-term trial data show?	After 24 years: 215 colorectal cancers on hormones vs 216 on placebo. Hazard ratio 0.95. [3]
Does it depend on whether I have a uterus?	Yes. That determines which WHI trial arm applies to you.
Does HRT replace colorectal cancer screening?	No. Screening follows your age and risk history, not your prescription.
What actually lowers risk?	On-time screening can find cancer earlier and can prevent cancer by finding removable precancerous growths. Only 37% of adults aged 45–49 were up to date in the 2026 ACS report. [16][23][24]

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Before you go further

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

One boundary, stated up front: Find My HRT Path does not diagnose or rule out colorectal cancer, set your screening schedule, or clear hormone therapy during or after cancer treatment. Nothing on this page can do those things.

---

What does the evidence actually say about HRT and colorectal cancer risk?

Answer: Randomized trial evidence shows no lasting effect in either direction. Observational studies consistently find fewer colorectal cancers among women who used hormone therapy, but the one large randomized trial that appeared to confirm this reversed itself after 24 years of follow-up. No major medical authority recommends hormone therapy to prevent colorectal cancer.

Let's define two things quickly, because the words get used loosely.

HRT (hormone replacement therapy), also called MHT (menopausal hormone therapy), means estrogen — sometimes with a progestogen — taken to treat menopause symptoms. This page is about that, not about gender-affirming hormones or cancer endocrine therapy.

Colorectal cancer is the umbrella term. Colon cancer and rectal cancer are its two halves. In the UK you'll hear "bowel cancer." Same disease family.

Now the shape of the evidence, in four layers:

1. No clear overall increase. No randomized trial discussed here showed a clear overall increase in colorectal cancer incidence.
2. Observational studies keep finding lower rates. Repeatedly, across countries and decades. Ever-use of hormone therapy was linked to a 38% lower risk in one pooled analysis of 8,220 postmenopausal women. [8]
3. Randomized evidence does not back a lasting protective effect. That's the layer most pages skip.
4. You can't read "fewer diagnoses" without also reading stage and mortality. This is where the whole story turns.

That fourth point deserves its own beat, because it's the thing that makes the rest of the page make sense.

Three different questions that sound like one

Outcome	What it measures	Why it can tell a different story
Incidence	How many cancers get diagnosed	Affected by biology and by how hard anyone was looking
Stage at diagnosis	How far it had spread when found	Fewer diagnoses is not good news if the ones found are bigger
Mortality	Deaths from colorectal cancer	The outcome that actually matters — and the one that takes longest to measure

Hold onto that. Every confusing thing about this topic comes from a page reporting one of those three and calling it the answer.

---

Did HRT really cut colorectal cancer risk by 44%?

Answer: Yes at first, and then no. In the Women's Health Initiative trial of estrogen plus progestin, there were 43 colorectal cancers in the hormone group versus 72 on placebo after 5.6 years. After 24 years of follow-up there were 215 versus 216, and the hazard ratio was 0.95. The early difference did not survive.

The Women's Health Initiative (WHI) ran the pivotal large randomized trials that still anchor this question. In this arm, 16,608 postmenopausal women who still had a uterus were randomly assigned to daily conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg — or to placebo. [4]

That's an oral pill combination. Write that down; it matters later.

The trial has now been reported three times. Most pages you'll find quote the first one and stop.

How the answer changed, report by report

Report	Follow-up	What it found	What the full reading has to include
2004 [4]	5.6 years	43 vs 72 cancers. HR 0.56. A 44% reduction.	Cancers in the hormone group were far more often node-positive: 59.0% vs 29.4%. Regional or metastatic disease: 76.2% vs 48.5%. [3][4]
2012 [5]	11.6 years total	Still fewer: 0.12% vs 0.16% per year. HR 0.72.	Cancers still more often node-positive (50.5% vs 28.6%) and higher stage (68.8% vs 51.4%). Investigators questioned the clinical meaning.
2024 [3]	24 years, 431 cancers	215 vs 216. HR 0.95 (0.79–1.15). Gone.	Colorectal cancer deaths were higher on hormones — 87 vs 69, HR 1.20 (0.87–1.65) — though not statistically significant.

Read that bottom row again. Twenty-four years, 431 cancers, and the difference is one case.

The damaging admission

We'd rather have told you HRT protects your bowel.

It is the one line in the entire menopause conversation that reads as unambiguously good news. It's on provider websites. It's in podcasts. It's the thing a friend told you last month. And for a site like ours — which does recommend telehealth providers, and does earn money when readers use them — it would be very convenient to leave it standing.

We're retiring it instead.

Here's why that's not the bad news it sounds like: what you actually needed was never a benefit claim. You needed to know which half of the evidence applies to you, what your own prescription's label says, and one rule about bleeding that could genuinely matter. Those three things are worth more than a statistic that didn't hold. You'll have all three by the time you finish this page.

Why the early number probably looked so good

This is the part that disappears from most summaries.

In the first six months of the trial, 54.1% of women taking estrogen plus progestin had vaginal bleeding, compared with 5.2% on placebo. Breast changes: 9.2% versus 2.0%. [3]

When the 2024 investigators adjusted for that bleeding and those breast changes, they found something specific: bowel examinations were significantly delayed in the hormone group (P = .005). [3]

Their own conclusion was blunt — about five years of this regimen produced no clinically meaningful benefit on colorectal cancer outcome. [3]

Our read, stated as ours, not as proven fact: the most straightforward explanation is that women on combined HRT were bleeding, their bowel investigations slipped, and cancers were found later and larger. That would explain the early "fewer cancers," the worse stage, and why the whole thing evaporated once follow-up ran long enough for the delayed cancers to surface. The WHI investigators raised this same possibility. It is a hypothesis the data supports, not a mechanism the data proves.

There's one more finding from 2004 that points the same direction. Among women in the hormone group, those who'd had vaginal bleeding beforehand had cancers with more positive lymph nodes than hormone-group women who hadn't bled — 3.8 nodes versus 0.7. [4]

Which brings us to the most practical section on this page.

---

I'm on HRT and I'm bleeding. Is that bowel cancer?

Answer: Vaginal bleeding and rectal bleeding are different events with different causes and different work-ups. Bleeding was common in the first months of the WHI combined-hormone trial — 54.1% versus 5.2% on placebo. That is exactly why blood seen in the toilet must never be assigned to HRT until someone has established where it came from. [3]

Here is the rule we'd want a friend to have.

"It's just the HRT" is only safe once somebody has established where the blood is coming from.

That sounds obvious written down. It is not obvious at 11pm when you've just started a new patch, you've been told spotting can happen in the first months, and you're trying to decide whether to bother anyone.

We are not telling you that bleeding on HRT means cancer. Many causes are not cancer. Unscheduled vaginal bleeding on hormone therapy has many ordinary explanations. What we're telling you is narrower and more useful: a new prescription has just handed you a ready-made explanation for bleeding, and that explanation can absorb attention a bowel symptom needed. The WHI analysis found delayed bowel examinations in the hormone group after accounting for bleeding and breast changes. [3]

How to describe what you've seen

Clinicians can act much faster when you give them the specifics. Before you call, note:

• Where you saw it. On the toilet paper, in the bowl, mixed into the stool, on your underwear, or on a pad.
• When. With a bowel movement, between them, or unrelated.
• What it looked like. Bright red, dark red, dark brown or black and tarry.
• How much. A streak, drops, clots, enough to color the bowl, or ongoing bleeding.
• How long. First time, or ongoing — and since what date.
• What changed recently. Started HRT, changed dose, changed route, changed anything else.

Then say the sentence that gets you the right appointment: "I've seen blood and I'd like it investigated, not assumed to be my HRT."

If you're on hormone therapy and bleeding vaginally in a pattern that worries you, that also deserves review — but from a different angle, and by the person who prescribed it. Two different investigations. Don't let one stand in for the other.

Continuous or heavy rectal bleeding, fainting or marked lightheadedness, or rectal bleeding with severe abdominal pain is not a routine telehealth question. Seek urgent or emergency care. [36]

Do not stop a prescribed medication on your own because of anything on this page. Medication changes belong with your prescriber. Symptom evaluation is separate and shouldn't wait for it.

---

Which bowel symptoms should never be blamed on HRT?

Answer: Blood in or on the stool, dark or black stool, a bowel change lasting more than a few days, unexplained iron-deficiency anemia, unexplained weight loss, persistent abdominal pain, or the feeling that a bowel movement does not empty you needs an in-person evaluation whether or not you take hormones. [25]

The list, plainly:

• A change in bowel habits — including diarrhea, constipation or narrowed stool — that lasts more than a few days
• A feeling that you still need to go after a bowel movement
• Blood in or on your stool, or rectal bleeding
• Dark brown or black stool that could contain blood
• Abdominal pain or cramping that persists
• Losing weight without trying
• Weakness, fatigue, low iron or a low red-blood-cell count you can't explain

Most of these turn out to be something other than cancer. That's true and it should be some comfort. It is also not a reason to skip finding out which something.

Screening and symptom evaluation are not the same thing

This distinction saves people. Most readers have never had it explained.

Your situation	What you need
No symptoms, due for testing based on age and history	Screening
Symptoms, unexplained anemia, or an abnormal exam	Diagnostic evaluation — a routine screening schedule is not the right tool
A positive stool, blood or imaging screening test	Timely follow-up colonoscopy — preferably within six months under the 2026 ACS guideline. [16]

A symptom does not get "covered" by a screening test you're due for. Different question, different pathway, different urgency.

One more thing: a telehealth menopause intake is not the right first stop for any of the symptoms above. We run a site that recommends telehealth providers and we're telling you that anyway.

---

Does it matter whether I still have a uterus?

Answer: It decides which WHI evidence applies to you. The early colorectal finding came only from the estrogen-plus-progestin arm, which enrolled women with a uterus. Women who'd had a hysterectomy took estrogen alone and showed no significant colorectal effect early or in long-term follow-up — hazard ratio 1.08 early and 1.13 later. [6][7]

The WHI ran two separate trials. Nearly every article you'll read blurs them into one.

	Estrogen + progestin (with a uterus)	Estrogen alone (after hysterectomy)
Who	16,608 women [4]	10,739 women [6][7]
What they took	Oral conjugated equine estrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg, daily	Oral conjugated equine estrogen 0.625 mg, daily
Early result	43 vs 72 cancers. HR 0.56 [4]	HR 1.08 (0.75–1.55). No significant difference. [6]
Long-term incidence	HR 0.95 at 24 years. Gone. [3]	0.14% vs 0.12% per year. HR 1.13 (0.83–1.58), P = .43 [7]
Colorectal-cancer deaths	87 vs 69. HR 1.20 (0.87–1.65), not significant [3]	34 vs 24. HR 1.46 (0.86–2.46), not significant [7]
Stage of cancers found	Worse in the hormone group [3][4]	No significant difference in grade, stage or location [7]
Bleeding signal	54.1% vs 5.2% in first 6 months [3]	Not the signal examined in this arm

Our read, again labeled as ours: the estrogen-alone arm is the internal comparison that makes the whole picture coherent. No apparent benefit. No stage shift. No difference in where or how advanced the cancers were. The combined arm had the early incidence gap, the bleeding signal and worse stage — and its incidence gap didn't last.

That's not proof of a single mechanism. Both mortality estimates above point mildly the wrong way and neither reaches statistical significance, which means neither belongs in your head as a finding. But it is a much more honest picture than "HRT protects the colon."

One practical takeaway: if you've had a hysterectomy, essentially none of the famous "HRT lowers colon cancer risk" material was generated in women in the estrogen-alone WHI arm.

Not sure which half applies to you? Whether you have a uterus usually determines whether systemic estrogen needs endometrial protection, and it determines which WHI arm is relevant. Find My HRT Path takes about 90 seconds and helps map the care model that fits your situation — including when the next step belongs in person. It does not calculate colorectal-cancer risk or clear hormone therapy. → Get your personalized HRT care-path match

---

What does the FDA label actually say about HRT and colorectal cancer?

Answer: The live PREMPRO/PREMPHASE prescribing information checked August 6, 2026 still reproduces the early WHI figure of six fewer colorectal cancers per 10,000 women-years in Clinical Studies. Prevention is not an approved use. The Pfizer labels reviewed do not specifically name colorectal cancer or family history as contraindications, but that absence is not personal clearance. [1][2]

We read the live PREMPRO/PREMPHASE prescribing information displayed by Pfizer — revision 4/2025 — plus the PREMARIN tablet and Vaginal Cream labels. We also checked the FDA's February 12, 2026 announcement approving boxed-warning changes for six menopausal hormone products. [1][2][26]

The Label Colorectal Ledger

Label section	What the reviewed labels say about colorectal cancer
Boxed Warning	The live 4/2025 PREMPRO/PREMPHASE document still contains cardiovascular-disease and dementia prevention language; FDA approved removal of several boxed-warning statements for six products in February 2026. Neither creates a colorectal-cancer indication. [1][26]
§1 Indications	Approved uses include moderate-to-severe vasomotor symptoms, vulvar/vaginal atrophy symptoms, and prevention of postmenopausal osteoporosis in specified circumstances. Colorectal-cancer prevention is not an approved use. [1][2]
§4 Contraindications	The reviewed Pfizer labels do not specifically name colorectal cancer, a personal history of colorectal cancer, or family history of colorectal cancer. They do contain broader contraindications that still require product-specific clinical review. [1][2]
§5.2 Malignant Neoplasms	The PREMPRO/PREMPHASE section addresses endometrial, breast and ovarian cancer — not colorectal cancer. [1]
§5.17 Exacerbation of Other Conditions	The PREMPRO/PREMPHASE list does not name a bowel disorder or colorectal cancer. [1]
§6.2 Postmarketing (GI)	Ischemic colitis appears among voluntarily reported gastrointestinal events. It is a blood-flow disorder, not colorectal cancer, and the label says frequency cannot be reliably estimated. [1]
§14.6 WHI Studies — estrogen + progestin	The historical 5.6-year table reports 6 fewer colorectal cancers per 10,000 women-years and 5 fewer hip fractures, alongside 7 more coronary events, 8 more strokes, 10 more pulmonary embolisms and 8 more invasive breast cancers. The global index showed 19 excess events per 10,000 women-years. [1]
WHI text — estrogen alone	Colorectal cancer was not a significant outcome in the estrogen-alone arm. [1][2]

Three findings fall out of that side-by-side label audit.

First: the label is accurate about what happened during the early treatment period — and incomplete for the long-term question. The six-fewer figure came from the 5.6-year WHI report. The 24-year follow-up found 215 versus 216 cases. The label is not proof that the benefit lasted, and it is not an instruction to use HRT for prevention. [1][3]

Second: the colorectal trial narrative also appears in the PREMARIN Vaginal Cream label. That does not turn a local vaginal treatment into a colorectal-prevention therapy. The number came from women taking daily oral conjugated estrogens plus medroxyprogesterone acetate, not vaginal cream. [2][3]

Third — and this is the one that matters if you've been refused: the reviewed labels do not specifically list colorectal cancer or family history of it as contraindications. That does not automatically make you a candidate. It means the next useful question is: Which actual contraindication, treatment interaction or individual risk are you relying on?

One current-label wrinkle belongs in plain sight. In February 2026, FDA approved changes removing cardiovascular-disease, breast-cancer and probable-dementia statements from the boxed warning of six menopausal hormone products. The live PREMPRO/PREMPHASE document we checked still displayed revision 4/2025 and the historical WHI colorectal table. We are reporting the text visible on August 6, 2026 rather than pretending every product document updates at the same moment. [1][26]

---

So why do so many studies say HRT lowers colon cancer risk?

Answer: Because most of them compare women who chose or were prescribed hormone therapy with women who didn't, and those two groups differ in more ways than the prescription. Differences in screening, health, health care access and prescribing habits can create or magnify an association. A lower rate does not prove hormones caused the protection.

This is the contradiction most likely to send you searching again, so let's settle it.

A randomized trial flips a coin and assigns you a treatment. Whatever differences show up afterward are more likely caused by the treatment, because the coin didn't care who you were.

An observational study watches what happened to people who made their own choices. It's valuable — bigger, more real-world, better at rare outcomes — but it can never fully remove the fact that hormone users and non-users are different people.

Different in ways that matter here, specifically:

• Women on hormone therapy see clinicians more often, so they get screened more often — and colonoscopy doesn't just detect cancer, it prevents it by removing polyps.
• Clinicians are less likely to prescribe systemic hormones to women who are already unwell.
• Most databases can't capture route, dose, duration, adherence, diet, weight, smoking, alcohol, or colonoscopy history properly.

No single one of these explains the whole association. Together they're why "hormone users had less colorectal cancer" isn't the same sentence as "hormones prevented colorectal cancer."

That said — the observational evidence is large, consistent, and interesting. Here's what it actually contains, assembled in one place. This is the part that usually takes five open tabs.

The observational ledger

Study	What it found	The catch
Pooled analysis of 8 studies, 3,898 cases + 4,322 controls [8]	Ever-use vs never: OR 0.62 (0.56–0.69). Estrogen-only 0.71; estrogen + progestin 0.76.	Self-reported exposure, no dose or duration, 98.3% of participants were white, and users may simply be screened more.
Same analysis, by tumor location [8]	Rectum 0.54, distal colon 0.57, proximal colon 0.71 — the weakest (P for difference vs distal = .01).	Location differences may reflect different tumor biology, not different hormone effects.
Same analysis, by tumor pathway [8]	Traditional pathway 0.63; alternate pathway 0.61; serrated pathway 0.81 (0.66–1.01) — not statistically significant.	Serrated tumors behave differently and are harder to classify consistently.
Israel MECC study, 2,460 women [11]	Adjusted OR 0.37 (0.22–0.62).	The association was not found in aspirin users, or in women doing intensive sports. If you already have those exposures, there's no measurable extra signal.
56,733 women, 960 cancers, mean 15 years [10]	Estrogen use of 10+ years: RR 0.74 (0.56–0.96). Sequential progestin under 15 days per cycle: RR 0.64 (0.43–0.95) — a stronger association than continuous combined therapy.	Regimen data from questionnaires; the sequential/continuous difference has not been tested in a trial.
28,486 women, 141-variant genetic risk score [12]	Hormone use was associated with lower colorectal-cancer odds across genetic-risk quartiles, with the strongest apparent association in the highest-risk quartile (P for interaction = 2.7 × 10⁻⁸).	Still observational. Not a personal calculator, and not a reason to take hormones.

That's a real body of evidence and we're not dismissing it. We're saying it answers the question "what happened to women who used hormone therapy?" — and the trial answers "what happens if you give hormone therapy to women?" Those aren't the same question. The randomized question is the one that gets closest to the treatment decision you are actually making.

---

Should I take HRT to lower my colorectal cancer risk?

Answer: No. The US Preventive Services Task Force gives a grade D recommendation against using combined or estrogen-only hormone therapy for the primary prevention of chronic conditions. That recommendation is about prevention in asymptomatic postmenopausal people — not about treating bothersome menopause symptoms. [13]

A grade D means the Task Force concluded there is no net benefit, or that harms outweigh benefits, for this preventive use. Both hormone pathways are covered. [13]

The 2022 evidence review translated the early combined-therapy result into absolute terms: 34 fewer colorectal cancers per 10,000 people over 5.6 years — 59 versus 93 — alongside statistically significant increases in invasive breast cancer, gallbladder disease, stroke, venous thromboembolism and probable dementia over the study periods. The apparent colorectal benefit also lost statistical significance after treatment stopped and then disappeared in the 24-year WHI report. [3][13]

Thirty-four per ten thousand over 5.6 years. Against that list. That's the actual prevention trade — and the long-term incidence result still ended at 215 versus 216.

The Menopause Society's 2022 position statement frames hormone therapy as having a favorable benefit-risk balance for appropriately selected women under 60 or within 10 years of menopause who have bothersome symptoms, with treatment individualized and reviewed periodically. It does not recommend HRT for colorectal-cancer prevention. [14]

An earlier estrogen-alone subgroup analysis showed an age interaction for colorectal cancer, but the interaction was no longer present after 13 to 18 years of extended follow-up. That correction matters: there is no reliable colorectal-cancer rule that says a specific starting age makes HRT protective or harmful. [13]

If this is your main reason, please don't

We'd rather lose you here than have you make a decision on a foundation that's already cracked.

If the colorectal line is the main reason you're considering HRT, it isn't a good enough reason. It will fall over the first time someone shows you the 24-year data. And if you don't have symptoms or another recognized indication that is genuinely costing you something — sleep, work, sex, temperature control, genitourinary comfort or bone protection in the right clinical context — colorectal prevention is not your treatment rationale.

→ Read our guide to non-hormonal options instead

If you do have symptoms that are costing you something, keep reading. The decision is real. It's just about something else.

---

Does the type of HRT change the answer — patch, pill, gel, or vaginal estrogen?

Answer: Route-specific colorectal evidence is sparse and not randomized. One prescription-database study found a stronger association with transdermal estrogen used for at least three years than with oral estrogen, but the estimate came from small numbers and nearly crossed 1.0. Choose route for the treatment goal and broader risk profile, not hoped-for colon protection. [9]

Start with the sentence that reframes this entire literature:

Every randomized colorectal number on this page comes from oral conjugated equine estrogens, with or without medroxyprogesterone acetate. Common current regimens such as transdermal estradiol with micronized progesterone have never been tested against colorectal-cancer incidence in a randomized trial.

Not "tested and found equal." Never tested for this outcome. Anyone who tells you a patch is better or worse for your colon is extrapolating.

What the route evidence does and doesn't show

The one meaningful oral-versus-transdermal comparison is a Canadian nested case-control study of 1,197 colorectal-cancer cases using prescription records: [9]

Compared with never-users	Odds ratio (95% CI)
Transdermal estrogen, 3+ years	0.33 (0.12–0.95)
Transdermal estrogen, under 3 years	0.69 (0.43–1.10)
Oral estrogen, 3+ years	0.75 (0.60–0.93)
Oral estrogen, under 3 years	0.90 (0.73–1.01)

Read the transdermal top row carefully. The confidence interval runs from 0.12 to 0.95 — an enormous range, built on a small exposed group in one province in the 1990s. It is the best direct route comparison we found and it is nowhere near strong enough to pick a patch over a pill for this reason.

What each category can and can't inherit

Category	What the colorectal evidence covers	What it does not cover
Combined systemic therapy	Daily oral conjugated equine estrogen + medroxyprogesterone acetate. No durable incidence benefit at 24 years. [3]	Transdermal estradiol with micronized progesterone or other combinations. Different drugs and routes, untested in a colorectal RCT.
Estrogen-only systemic therapy	Oral conjugated equine estrogen alone. No significant effect either way. [6][7]	Patches, gels, sprays and other doses. No colorectal-specific randomized basis.
Low-dose vaginal estrogen	No randomized colorectal evidence. It is a local treatment for genitourinary symptoms.	It should not inherit the systemic oral-trial result even though class text on the PREMARIN Vaginal Cream label carries the WHI narrative. [2]
Compounded hormone products	No colorectal-outcome trial. Compounded products are not FDA approved; FDA does not review them for safety, effectiveness or quality before marketing. [27]	They cannot inherit the evidence or approval status of an FDA-approved product because an ingredient name sounds similar. We will not describe them as equivalent, safer or more natural.

Why the progestogen name matters

The WHI combined arm used medroxyprogesterone acetate (MPA) — a synthetic progestin. It is not the same molecule as micronized progesterone, which is commonly prescribed alongside estradiol.

Don't let a headline turn "MPA" into "progesterone." They are different drugs, and there is no colorectal randomized-trial evidence for micronized progesterone.

There is one observational hint worth knowing: sequential progestin taken fewer than 15 days per cycle was associated with a stronger reduction than continuous combined therapy, RR 0.64 in one questionnaire-based cohort. It was never randomized. Interesting, not actionable. [10]

So what should route actually be decided on?

What symptom or indication you are treating. Whether treatment needs to be systemic or local. Whether you have a uterus. Your clotting, cardiovascular, liver, migraine and bleeding history. Medication interactions. What you can use consistently. Cost, insurance and state access. Those are the real questions for the consult.

Route changes care. It does not create a colorectal-cancer advantage. Midi Health is one care-model option for a reader who wants a live video visit and a service that says it can order needed labs or screening and send patients to local labs and imaging centers. [28][29] → Read the verified Midi Health review One limitation, stated plainly: Midi does not treat Medicaid or Medi-Cal patients, even as self-pay patients. Medicare beneficiaries can self-pay, but Midi says they cannot submit claims related to Midi visits, medications or associated services. [28]

---

What if bowel cancer runs in my family?

Answer: A family history of colorectal cancer was not specifically named as a contraindication in the Pfizer hormone labels we reviewed. But it may change the evidence that applies to you: in a 2025 pooled analysis of three cohorts, the lower colorectal-cancer association seen among hormone users disappeared in women with a moderate-to-strong family-history score. [1][2][15]

This is the most decision-relevant finding on the page for anyone in this group, and almost nobody has translated it for a general audience.

The 2025 family-history flip

Researchers pooled three prospective cohorts — an analytic set of 24,488 women, 310,789 person-years and 405 colorectal cancers — and built a family-history risk score for each woman. People with known variants in BRCA1/2 or the major Lynch-syndrome genes were excluded, so this analysis addresses non-syndromic family history rather than known hereditary cancer syndromes. [15]

The threshold was 0.4, roughly the risk contribution of a 50-year-old woman with one parent diagnosed around age 55.

Group	Ever-use of HRT vs never	Hazard ratio (95% CI)
All women in the pooled cohorts	Lower observed risk	0.73 (0.59–0.90)
Family-history score below 0.4	Lower observed risk	0.66 (0.53–0.83)
Family-history score 0.4 or above	No protective association detected	1.21 (0.74–1.98)
Difference between groups	—	P = .03

The paper's corrected body-text estimate below the threshold was 0.66; its abstract reported a slightly different figure. We use the corrected body table. [15]

Read the second-to-last row honestly. The confidence interval runs from 0.74 to 1.98 and crosses 1.0 in both directions. It does not show harm. It shows that the protective association quoted from general observational studies was not present in the higher-family-risk group, and that the estimate in that group is imprecise.

Which means: if bowel cancer runs in your family, the "HRT protects your colon" headline was probably never the right decision tool for you. That's not a reason to avoid hormone therapy. It's a reason to decide on symptoms and the full benefit-risk picture — and to take your family history and screening plan seriously.

What actually changes with family history — and what doesn't

Your situation	What genuinely changes	What does not automatically change
One relative diagnosed later in life	Gather the exact relative, cancer site and age at diagnosis; ask whether average-risk screening still applies	HRT eligibility based on a headline
Several relatives, or a young diagnosis	Genetic counseling may be appropriate; screening may start earlier or occur more often	Whether menopause symptoms deserve treatment
Previous advanced or multiple polyps	Your colonoscopy surveillance plan, set from pathology, size, number and prior findings	The hormone decision by itself
Lynch syndrome or FAP	Genetics and GI own the screening and prevention plan	Population-average HRT findings do not settle the question
Inflammatory bowel disease affecting the colon	GI-led surveillance may begin earlier and repeat more often	Your menopause treatment is not decided by an average-risk table
Previous abdominal or pelvic radiation	Starting age, test type and interval may change under a survivorship plan	HRT is not automatically ruled in or out

Lynch syndrome specifically

Let's be exact, because vagueness here does real harm.

The oncological safety of menopausal hormone therapy has not been specifically studied in the Lynch-syndrome population. Current recommendations rely on indirect evidence and individualized risk assessment. [17]

What is on record: a Society of Gynecologic Oncology clinical-practice statement endorsed by The Menopause Society says that people with Lynch syndrome — and BRCA carriers without a breast-cancer history — may use hormone therapy to improve quality of life. [18]

That is not a universal clearance. Lynch risk and the timing of risk-reducing surgery vary by gene, age, childbearing plans, family history and prior cancer. If the ovaries are removed before the usual age of menopause, the abrupt hormone loss creates its own bone, cardiovascular, sexual and quality-of-life questions. Those deserve a plan, not an automatic refusal.

Who owns this decision: your genetics or GI team and a clinician with menopause expertise, together. Not an asynchronous online intake alone.

If you carry a Lynch variant, have FAP, or are already under high-risk surveillance, your first conversation belongs with the team managing that risk. Online menopause care may become useful later, but it is not the place to settle the cancer question.

---

Can you take HRT after colorectal cancer?

Answer: Colorectal cancer was not specifically named as a contraindication in the Pfizer labels reviewed, and observational survivor evidence is reassuring. A 2024 linked-records study of 182,589 women found no higher cancer-specific mortality among systemic HRT users after diagnosis. No randomized trial has tested starting HRT after colorectal-cancer treatment, so the decision belongs with your oncology team. [1][2][19]

This group is growing, and it's badly served.

Colorectal cancer is increasingly diagnosed under 50. Pelvic radiotherapy for rectal cancer can damage ovarian function. Removing the ovaries during surgery causes immediate menopause. Women can land in abrupt, severe menopause in their thirties or forties while every clinician they ask is deferring to a different clinician.

What the evidence shows

• A UK linked-records cohort of 182,589 women across 17 non-breast cancer sites, diagnosed from 1998 through 2019, found that 7% used systemic HRT after diagnosis. There was no evidence of higher cancer-specific mortality at any site; the colorectal estimate was HR 0.79 (0.70–0.90). [19]
• That apparent colorectal survival advantage weakened in sensitivity analyses. Compared with vaginal-estrogen users, the estimate was HR 0.93 (0.78–1.10); among stage I–III colorectal cases, it was HR 0.87 (0.68–1.11). Those confidence intervals cross 1.0. [19]
• A 2019 systematic review and meta-analysis pooled five cohorts and 10,013 colorectal-cancer survivors. Current HRT use was associated with lower colorectal-cancer-specific mortality and all-cause mortality; former use was not. [20]
• A Swedish nationwide cohort of 7,814 women found that estrogen-only therapy used before diagnosis was associated with improved survival. It did not answer the question of starting treatment after therapy. [21]
• A 2023 narrative review reached a broadly reassuring conclusion while emphasizing the observational design and lack of randomized survivor trials. [22]

The gap nobody names

We initially read this evidence too narrowly. That was wrong. The strongest new cohort did study systemic HRT use after cancer diagnosis.

The real gap is different: these are observational data. Healthier survivors may be more likely to receive HRT. Prescribing patterns, stage, comorbidity, socioeconomic factors and access to follow-up can shape the result. The sensitivity analyses that pulled the colorectal estimate toward no difference are exactly why the apparent survival advantage cannot be sold as a benefit. [19]

What that means practically: the evidence is reassuring enough to support a serious conversation. It is not strong enough for an online article to give you a green light, and we won't pretend otherwise.

What to ask your oncology team

1. Given my cancer's site, stage, molecular features and treatment, is there any reason hormone therapy would interfere with surveillance or change my long-term risk?
2. Does my clotting, cardiovascular, liver or bleeding history change the calculation independently of the cancer?
3. If systemic therapy isn't right, is a local vaginal treatment reasonable for my genitourinary symptoms?
4. Did chemotherapy, radiation or surgery cause menopause — and what is the plan for bone, cardiovascular and sexual health over the next 20 years?
5. Who owns this decision going forward: oncology, a menopause clinician, or both together?

If you're managing menopause after colorectal-cancer treatment, order matters more than provider. Find My HRT Path can help you identify when the next step belongs in person and which provider model may fit afterward. It cannot clear hormone therapy or replace oncology review. → Map the care path before your next consult

---

Does HRT change when you should get screened for colorectal cancer?

Answer: No. Hormone therapy does not replace, delay or create a separate screening schedule. Under the American Cancer Society's 2026 guideline, average-risk adults start at 45; people at increased risk may need a different test, an earlier start or a shorter interval. Only 37% of adults aged 45–49 were up to date in the 2026 ACS report. [16][23][24]

Here's the section we'd keep if we had to delete every other word on this page.

Why this is urgent right now

The American Cancer Society's 2026 colorectal-cancer statistics report tells a story that hasn't reached most people: [23][24]

Fact	2026 figure
Estimated new US colorectal-cancer cases	158,850
Estimated deaths	55,230
Rank as a cause of cancer death in adults under 50	First
Incidence trend, ages 20–49	Up 3% per year, driven by distal-colon and rectal cancers
Incidence trend, ages 50–64	Up 0.4% per year
Share of new cases in adults under 65	45%, up from 27% in 1995
Under-50 cancers diagnosed at regional or distant stage	Three in four
Adults aged 45–49 up to date with screening	37%
Ages 65+	Incidence and mortality still falling by more than 2% per year

Look at the 50–64 row. That's the age band of many people reading this page. Rates are rising, while screening remains the action that can actually change the outcome.

One editorial observation, ours: the tumors rising in younger adults are disproportionately distal and rectal — the same locations where one observational hormone analysis showed the strongest inverse association. [8][23] That's an interesting research question. It is emphatically not a prevention argument, and we won't dress it up as one.

What the ACS 2026 guideline actually says

These are the current average-risk options and intervals. [16]

Screening option	ACS 2026 interval / place in the guideline
High-sensitivity guaiac fecal occult blood test (gFOBT)	Every year
Fecal immunochemical test (FIT)	Every year
Multi-target stool DNA (mt-sDNA)	Every 3 years
Multi-target stool RNA (mt-sRNA)	Every 3 years
Colonoscopy	Every 10 years
Flexible sigmoidoscopy	Every 5 years
CT colonography	Every 5 years
Blood-based screening	A targeted option for people who decline or do not complete preferred stool-based tests or visual exams; not a preferred first option

The age framework:

• Start at 45 for average-risk adults.
• Continue through 75 when health and life expectancy support screening.
• Ages 76–85: decide individually with a clinician based on health, prior screening, life expectancy and preference.
• Over 85: screening is no longer recommended.
• Every positive non-colonoscopy screening test needs timely colonoscopy — preferably within six months. [16]

That last line is the one people miss. A stool or blood screening test isn't finished when it comes back positive. It's finished when the follow-up colonoscopy is done.

Who is not average risk: family history that changes risk, prior adenomas or colorectal cancer, inflammatory bowel disease affecting the colon, a hereditary syndrome, or prior abdominal/pelvic radiation. Your plan may start earlier, use colonoscopy specifically, or repeat more often. A general interval table cannot set it for you.

And no — don't stop your HRT before a colonoscopy

Give the endoscopy team a complete list of every prescription, over-the-counter drug and supplement you take, and follow its written preparation instructions. If the team wants anything changed, it will tell you. Don't preemptively stop a prescribed medication because of an article.

---

Putting it together: how should colorectal risk affect your HRT decision?

Answer: Make the hormone decision based on the symptom or approved indication you're treating and your complete benefit-risk picture — not a hoped-for colorectal benefit. Make the colorectal decision separately: act on symptoms, know your risk category and stay current on the screening or surveillance plan that actually applies to you.

Two decisions. One page. They should not be tangled together.

The sequence

1. Name what you're treating. Hot flashes, night sweats, sleep disruption, genitourinary symptoms, or bone-loss prevention in the right clinical context. If you can't name the treatment goal, stop there.
2. Name the treatment category. Systemic or local. Estrogen alone or estrogen plus endometrial protection. FDA-approved or compounded. The exact product, route and dose.
3. Review the whole risk history. Clotting, cardiovascular, liver, breast, endometrial, bleeding, age, timing, medications and contraindications. Don't let the colorectal question crowd out the factors that actually change the prescription.
4. Classify colorectal risk separately. Average risk, family history, prior polyps, hereditary syndrome, IBD, radiation history, prior cancer, current symptoms and screening status.
5. Pick the right care setting. Routine menopause consult, primary care, GI, genetics, oncology-informed menopause care, or urgent symptom evaluation.
6. Decide, then set a review date. Write down the goal, expected benefit, side effects, unresolved questions and when the plan will be revisited.

Find yourself in this table

If this is you	Best next step	Don't conclude
Average risk, no bowel symptoms, weighing HRT	Decide on the actual menopause benefits and risks; keep screening on schedule	That HRT will prevent colon cancer
On HRT, screening overdue	Book the screening; review HRT separately	That HRT lowers your need to screen
New bowel symptom after starting or changing HRT	Contact an in-person clinician with both the symptom and medication timeline	That timing proves hormones caused it
Moderate or strong family history	Ask whether you need genetics and a personalized screening plan	That the general observational "protective" finding applies to you [15]
Lynch syndrome or FAP	Genetics and GI first, menopause expertise alongside	That population-average findings settle it
Prior colorectal cancer	Oncology and menopause expertise, together	That an article can clear treatment
Only vaginal or urinary symptoms	Ask about local and non-hormonal options	That systemic trial data ranks local treatments by colorectal safety
Starting systemic HRT later in life	Review the full age-, timing- and health-specific benefit-risk picture	That an old colorectal subgroup creates a personal age rule [13][14]

Twelve questions worth bringing to your appointment

1. What symptom or recognized indication are we treating?
2. Is this systemic or local, and is the exact product FDA approved or compounded?
3. What exactly is the estrogen, the progestogen if any, the route and the dose?
4. Does anything in my history make this plan a poor fit, independent of colorectal risk?
5. Am I average risk for colorectal cancer, or does my history change that?
6. Given the exact relatives, their ages at diagnosis and how many — do I need genetic counseling?
7. What did my previous polyp pathology show, and when is my next colonoscopy due?
8. Which screening test is right for me, and what happens if it is abnormal?
9. Do my current bowel symptoms need diagnostic testing rather than routine screening?
10. If I've had colorectal cancer, what does my oncology team need to review first?
11. What would make us change or stop this hormone plan?
12. When are we reviewing all of this again?

Print that. Take it in. A clinician can move much faster when the questions are already specific.

---

How we researched this, and what we did not verify

Answer: We prioritized randomized trials for cause-and-effect questions, used observational studies to describe patterns, read the live Pfizer labels ourselves, and kept the exact drug, population and follow-up period next to every number. We also re-checked every provider claim in the late-page comparison against provider-owned pages on August 6, 2026. Where the evidence cannot answer a question, we say so.

Who wrote it: The HRT Index editorial team. There is no clinician byline because no clinician reviewed this page, and we're not going to invent one.

How it was produced:

1. We read the live PREMPRO/PREMPHASE prescribing information displayed by Pfizer — sections 1, 4, 5, 6.2 and 14.6 — and recorded which sections mention colorectal cancer and which do not. [1]
2. We checked the PREMARIN tablet and Vaginal Cream labels for the same WHI language, and checked FDA's February 2026 labeling-change announcement. [2][26]
3. We read the 2004, 2012 and 2024 WHI combined-therapy reports as one trial reported at three time points rather than three separate proofs. [3][4][5]
4. We read the estrogen-alone incidence, stage and mortality reports. [6][7]
5. We read the pooled subtype/location analysis, route comparison, regimen cohort, Israel study, genetic-risk analysis and 2025 family-history paper, including their stated limitations. [8]–[12][15]
6. We confirmed the USPSTF prevention recommendation and corrected the earlier age-subgroup language against its full evidence review. [13]
7. We confirmed The Menopause Society's current position statement, the 2026 ACS screening guideline, its exact intervals, and the 2026 ACS statistics report. [14][16][23][24]
8. We read the 2024 post-diagnosis cancer-survivor cohort and its colorectal sensitivity analyses, plus the survivor meta-analysis. [19][20]
9. We re-checked Midi, Sesame, Hers and Winona care models, medication categories, published prices or checkout caveats, lab policies, access limits and material cancellation terms from provider-owned sources. [28]–[35]

The HRT Index Verification Standard is our documented review process: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule — top providers monthly, the full roster quarterly. It is never a numeric score. We evaluate providers on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, access.

⚠️ What we did not verify

• We did not review your medical records, imaging, pathology or treatment plan. Nothing here is personalized clearance.
• We did not audit every menopausal hormone product label on the US market. The label ledger is explicitly limited to the PREMPRO/PREMPHASE and PREMARIN-family documents named in the table.
• We did not enroll in the four provider programs or independently test clinical quality. Provider-owned pages can verify what a company publishes; they cannot prove how every visit will go.
• Sesame's current subscription price was not displayed consistently in the public page text we verified. The table labels it "confirm at enrollment" rather than guessing. Its published medication-cost, lab and refund terms were verifiable. [30]
• The 2025 family-history paper's abstract and corrected body table report slightly different below-threshold estimates. We use the body-table HR of 0.66. [15]
• We publish no patient testimonials on this page. A testimonial here would risk implying that one person's cancer or HRT outcome predicts another's. We use labels, trials, guidelines and dated commercial facts instead.

Change log

Date

What changed

August 6, 2026

Corrected ACS symptom timing and added exact 2026 screening intervals; narrowed universal FDA-label claims to the labels actually reviewed; added FDA's February 2026 labeling update; corrected the USPSTF absolute-risk and age-subgroup language; corrected the survivor evidence to reflect post-diagnosis HRT use; re-verified all provider facts, prices and limitations; removed unbuilt tool outputs and broken/internal placeholder links.

---

Which online HRT providers make sense if you're weighing this?

Answer: No online HRT provider changes colorectal-cancer risk. Once bowel symptoms and screening are handled, compare the care model: live video versus asynchronous intake, FDA-approved versus compounded lanes, outside labs or imaging, price transparency, insurance, and access limits. With any red-flag bowel symptom, none of these providers is your next step.

Provider facts last verified: August 6, 2026. Prices and policies can change; confirm the exact prescription, total cost and state eligibility before paying.

Provider-stated vs verified comparison

Provider	Care model	Medication lane	Labs / outside evaluation	Price and payment verified August 6, 2026	Material limitation
Midi Health	Live video visits; available in all 50 states [28][29]	Prescribes according to clinical fit, including FDA-approved options; do not treat the company itself as an "FDA-approved provider"	Says it orders needed labs/screening and sends patients to local labs and imaging centers [29]	Most PPO plans; self-pay $250 initial visit, $150 continued-care visit [28]	No Medicaid or Medi-Cal, even self-pay. Medicare beneficiaries may self-pay but may not submit Midi-related claims. [28]
Sesame	Choose a clinician; live video visits and messaging [30]	Provider may prescribe FDA-approved hormonal or non-hormonal options; Sesame also discusses compounded BHRT, which remains a separate, non-FDA-approved category [27][30]	Basic labs are included if ordered: CBC, A1c, thyroid, lipid panel and CMP, with state-specific lab/payment exceptions [30]	Confirm subscription price at enrollment. Medication costs are excluded and vary by insurance/pharmacy. Sesame does not bill insurance. [30]	First month is nonrefundable after the initial visit; cancel before the next cycle to avoid renewal. NY/NJ/RI and ND have direct lab-payment exceptions. [30]
Hers	Online assessment and ongoing provider access [31]	Eligible customers may receive oral or transdermal estradiol and progesterone; exact option depends on clinical eligibility and availability [31]	Routine HRT labs are not usually required, but Hers says a provider may recommend testing for younger age, unclear symptoms or other possible causes [32]	Oral medication from $79/month with a 12-month plan; patches from $134/month with a 12-month plan; cash-pay model [31]	The lowest published monthly prices require a 12-month plan. It is not the strongest fit when you need a live exam or a clearly published imaging/referral pathway.
Winona	Asynchronous intake and portal messaging; no phone/video clinician visits; replies typically within 24–48 hours [34]	Winona states its estrogen tablets, estrogen patches and progesterone capsules are FDA approved. Its creams are compounded and not FDA approved. The lanes must stay separate. [27][33][34]	Does not require routine hormone testing and does not publish a routine imaging pathway [34]	Estrogen tablets from $54/month, patches from $149/month, progesterone capsules from $39/month; cash pay; HSA/FSA accepted [33][34]	HRT ages 35–59 only; limited state/territory list; orders become noncancelable/nonrefundable after a 24-hour processing window. [34][35]

What "verified" means here: we confirmed that each statement appears on a provider-owned page on the date above. It does not mean The HRT Index observed the visit, verified an individual clinician's decision, or guarantees the checkout result.

Midi Health is the narrowest fit for this page when the reader wants a live conversation and a provider that publicly describes outside lab and imaging coordination. That is a care-path advantage, not evidence that Midi makes HRT safer for the colon. Its Medicaid/Medi-Cal exclusion is a real dealbreaker, and Medicare remains self-pay without claim submission. [28][29]

Sesame publishes included basic labs when ordered. Medication costs are separate, and the current subscription price needs confirmation at enrollment. Its value is flexible live-video access and that defined lab bundle — not an automatic answer to a bowel symptom. [30]

Hers does not publish a blanket no-lab policy. Its guidance says routine labs are often unnecessary for a typical menopause diagnosis, while testing may be ordered when age, symptoms or other conditions make it useful. The practical limitation is the asynchronous model and the lack of a clearly published routine imaging pathway. [31][32]

Winona has a clean FDA-approved lane and a separate compounded lane. We include only provider-stated prices for the exact FDA-approved forms named above and do not repeat Winona's broader marketing claims about compounded or "bioidentical" products. Its age/state limits, asynchronous communication and 24-hour cancellation window are material. [33]–[35]

Why we left some providers off this page

We've excluded compounded-only providers, including one with which we have an affiliate relationship.

Every randomized number on this page comes from FDA-approved oral products studied in controlled trials. Putting a compounded formulation beside that evidence without a hard boundary would imply the evidence transfers. It doesn't. Compounded drugs are not FDA approved, and FDA does not verify their safety, effectiveness or quality before marketing. [27]

If your screening is current, you have no red-flag bowel symptoms, and menopause symptoms are what's actually costing you something, the colorectal question is settled: choose the care model on its real merits. → Compare the full Midi Health verification · Read the Hers menopause review · Read the Winona HRT review

---

Frequently asked questions

Answer: These are the remaining questions most likely to change what you do next: cause versus prevention, route, family history, prior cancer, bleeding, screening intervals, and colonoscopy. The answers below keep population evidence separate from personal clearance and show when the next step belongs with a clinician rather than an online HRT program.

Does HRT cause colorectal cancer? No clear overall increase has been shown in the randomized trials discussed here. That is not the same as proving every product, route and population has been tested; the randomized evidence is dominated by oral conjugated equine estrogens with or without medroxyprogesterone acetate. [3][6][7]

Does HRT prevent colon cancer? No authority cited here recommends it for that purpose. The early randomized reduction in combined therapy disappeared after 24 years, and USPSTF recommends against using hormone therapy for primary prevention of chronic conditions. [3][13]

Why does the FDA label still mention six fewer colorectal cancers? The label accurately reports the early 5.6-year WHI treatment-period result. It does not include the 24-year null incidence result in that historical table, and colorectal-cancer prevention is not an approved indication. [1][3]

Is rectal bleeding a side effect of HRT? Expected or unscheduled vaginal bleeding is not the same event as rectal bleeding. Blood seen with stool, dark or black stool, or uncertainty about the source needs separate evaluation rather than being assigned to a new prescription. [3][25]

Can I take HRT if my mother had bowel cancer? Family history was not specifically named as a contraindication in the Pfizer labels reviewed. It can change your screening plan, and a 2025 pooled analysis found that the lower observational association among hormone users was not present in the moderate-to-strong family-history group. [1][2][15]

Can I take HRT with Lynch syndrome? This page cannot clear that. HRT safety has not been specifically studied in Lynch syndrome, though SGO guidance endorsed by The Menopause Society says Lynch patients may use hormone therapy to improve quality of life. Coordinate genetics, GI and menopause care. [17][18]

Is a patch safer than a pill for colon cancer risk? There is no reliable randomized evidence either way. One database study found a stronger association with long-term transdermal use, but its estimate was wide and observational. Choose route based on treatment goal and the broader risk profile. [9]

Does vaginal estrogen affect colorectal-cancer risk? There is no randomized colorectal-outcome evidence for low-dose vaginal estrogen. The WHI colorectal narrative appearing in the PREMARIN Vaginal Cream label comes from a systemic oral trial and should not be treated as evidence that vaginal cream prevents colon cancer. [2][3]

Does progesterone affect colon-cancer risk? The WHI combined arm used medroxyprogesterone acetate, not micronized progesterone. Micronized progesterone has not been tested for colorectal-cancer incidence in a randomized trial, so the WHI result cannot simply be transferred to it. [3]

Can HRT cause colon polyps? Current evidence does not support telling readers that menopausal hormone therapy causes polyps. If you have a polyp history, surveillance is set from pathology, size, number and previous findings — not by whether you take hormones.

I've had colorectal cancer. Can I take HRT? Post-diagnosis observational evidence is reassuring, including a 2024 cohort that found no higher cancer-specific mortality among HRT users across 17 cancer sites. The colorectal association weakened toward no difference in sensitivity analyses, and there is no randomized initiation trial. Take the question to oncology. [19][20]

Should I stop HRT before a colonoscopy? Don't stop a prescription because of an article. Give the endoscopy team your complete medication and supplement list and follow its written instructions.

Does HRT change when I need colorectal screening? No. There is no separate schedule for hormone users. Average-risk screening starts at 45 under ACS guidance; family history, polyps, IBD, hereditary syndromes, radiation history, prior cancer and symptoms can change the plan. [16]

What are the 2026 colorectal-screening intervals? ACS lists yearly FIT or high-sensitivity gFOBT; stool DNA or stool RNA every three years; colonoscopy every ten years; and flexible sigmoidoscopy or CT colonography every five years for average-risk screening. A positive non-colonoscopy test needs timely colonoscopy. [16]

Are bowel changes a side effect of HRT or a sign of cancer? Timing alone cannot answer that safely. A bowel change lasting more than a few days, blood, dark stool, persistent pain, unintended weight loss, weakness or unexplained anemia needs assessment even though many causes are not cancer. [25]

Does the age I start HRT change my colorectal-cancer risk? There is no reliable colorectal-specific starting-age rule. An earlier estrogen-alone age interaction disappeared with extended follow-up; the broader HRT benefit-risk balance still depends on age, time since menopause, symptoms and health history. [13][14]

---

What is the bottom line on HRT and colorectal cancer risk?

Answer: Menopausal hormone therapy has not shown a clear overall increase in colorectal-cancer incidence, and it is not a prevention strategy. The famous 44% reduction came from one oral regimen in women with a uterus and disappeared after 24 years. Estrogen alone never showed a significant benefit. The FDA label still reports the early trial-period figure.

So make two separate plans.

Plan one is your hormone decision — based on the symptom or recognized indication that is actually costing you something, your uterus status, route, complete risk history, product category and access. Colorectal prevention belongs nowhere near the deciding column.

Plan two is your bowel plan — get current on screening from age 45 if you're average risk, know whether your history puts you outside the average-risk schedule, and never let "it's probably just the HRT" stand in for finding out where blood is coming from.

Do both. They're both yours.

Still not sure which HRT program is right for you? Use our free 90-second care-path tool. → Find My HRT Path Find My HRT Path helps you plan the next care setting and provider model. It does not diagnose colorectal cancer, replace screening, set surveillance, or clear hormone therapy during or after cancer.

---

Sources

1. PREMPRO/PREMPHASE Prescribing Information, Wyeth Pharmaceuticals LLC/Pfizer, revision shown 4/2025; live document checked August 6, 2026. Sections 1, 4, 5, 6.2 and 14.6.
2. Pfizer labeling for PREMARIN tablets and PREMARIN Vaginal Cream; live documents checked August 6, 2026.
3. Chlebowski RT, Aragaki AK, Pan K, et al. Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial. J Clin Oncol. 2024;42(30):3530–3536.
4. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350(10):991–1004.
5. Simon MS, Chlebowski RT, Wactawski-Wende J, et al. Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol. 2012;30(32):3983–3990.
6. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291(14):1701–1712.
7. Lavasani S, Chlebowski RT, Prentice RL, et al. Estrogen and colorectal cancer incidence and mortality. Cancer. 2015.
8. Labadie JD, Harrison TA, Banbury B, et al. Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location. JNCI Cancer Spectr. 2020;4(5):pkaa042.
9. Csizmadi I, Collet JP, Benedetti A, Boivin JF, Hanley JA. The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk. Br J Cancer. 2004;90(1):76–81.
10. Johnson JR, Lacey JV, Lazovich D, et al. Menopausal Hormone Therapy and Risk of Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(1):196–203.
11. Rennert G, Rennert HS, Pinchev M, et al. Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol. 2009;27(27):4542–4547.
12. Tian Y, Lin Y, Qu C, et al. Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk. Br J Cancer. 2024;130:1687–1696.
13. US Preventive Services Task Force. Final Recommendation Statement and Evidence Summary, 2022.
14. The North American Menopause Society. The 2022 hormone therapy position statement. Menopause. 2022;29(7):767–794.
15. MacInnis RJ, Jenkins MA, Milne RL, et al. Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk. JNCI Cancer Spectr. 2025;9(1):pkae121.
16. American Cancer Society. 2026 colorectal cancer screening guideline update, including test intervals and follow-up-colonoscopy guidance; checked August 6, 2026.
17. Yongue G, et al. Risk of Cancer With Hormone Replacement Therapy: A Narrative Review. BJOG. 2026. doi:10.1111/1471-0528.70176.
18. Society of Gynecologic Oncology. Hormone therapy in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer. Clinical practice statement endorsed by The North American Menopause Society. Gynecol Oncol. 2020.
19. Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records. Br J Cancer. 2024.
20. Jang YC, Huang HL, Leung CY. Association of hormone replacement therapy with mortality in colorectal cancer survivor: a systematic review and meta-analysis. BMC Cancer. 2019;19:1199.
21. Prediagnostic use of estrogen-only therapy is associated with improved colorectal cancer survival in menopausal women. Acta Oncol. 2021;60(7):881–887.
22. Fiol G, Lete I, Nieto L, et al. Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality. J Clin Med. 2023;12(16):5263.
23. Siegel RL, et al. Colorectal cancer statistics, 2026. CA Cancer J Clin. 2026.
24. American Cancer Society. 2026 colorectal-cancer statistics research summary, March 2026.
25. American Cancer Society. Colorectal Cancer Signs and Symptoms, checked August 6, 2026.
26. US Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products, February 12, 2026.
27. US Food and Drug Administration. Compounding and the FDA: Questions and Answers, checked August 6, 2026.
28. Midi Health. Pricing & Insurance, checked August 6, 2026.
29. Midi Health. How Midi Works, checked August 6, 2026.
30. Sesame. Online Menopause Treatment, including medication-cost exclusions, labs, state exceptions and refund terms; checked August 6, 2026.
31. Hers. Does Insurance Cover HRT for Menopause?, including oral/transdermal options and 12-month-plan pricing; checked August 6, 2026.
32. Hers. HRT Blood Test: Do I Need Labs for HRT?, checked August 6, 2026.
33. Winona. Menopause Treatments and Published Product Prices, checked August 6, 2026.
34. Winona. Frequently Asked Questions, including FDA-approved vs compounded categories, states, age limits, care model and payment; checked August 6, 2026.
35. Winona Help Center. Canceling a Refill, updated January 23, 2026; checked August 6, 2026.
36. Mayo Clinic. Rectal bleeding: When to see a doctor, checked August 6, 2026.

The HRT Index earns a commission if you use some provider links on this page. It does not change what we publish — including the fact that this page retires a claim several providers still repeat and excludes compounded-only programs from this comparison. See our affiliate disclosure.